UNP’s platform combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening, enabling the rapid generation of drug-like macrocycles that bind challenging targets ...

Under the terms of the agreement, Sobi will acquire 90% of Apellis’ ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis will also be eligible for up to $25 million in milestone payments ...

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...

Transition to U.S. reporting status to take effect on January 1, 2026 ...

Greg joins Genmab from AstraZeneca (AZ), where he spent more than 20 years working in North America, Europe and Asia. For the last 12 years, he was part of the Legal Senior Management Team, holding ...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Genitourinary Tumor Study Ongoing with Active Screening and Enrollment. MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-o ...

Alvotech and Advanz Pharma have previously entered into partnership agreements for biosimilar candidates to more than ten reference biologics. The companies expect to launch their first biosimilars in ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

The randomized, placebo-controlled trial is evaluating the safety and efficacy of three dose levels of RPN-001 in men with low testosterone and impaired semen quality. The study plans to enroll ...

À la date de résiliation de ce contrat, les moyens suivants figuraient au compte de liquidité : ...